跳至主要内容
临床试验/NCT01373749
NCT01373749Unknown不适用

Compare of Continued Nitro Oxide Inhalation and Nitro Oxide Inhalation Continued With Oral Sildenafil on Treatment of Neonatal Persistent Pulmonary Hypertension

Third Military Medical University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2011年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
40
试验地点
1
主要终点
persistent normal pulmonary artery pressure

研究概览

简要总结

Nitro Oxide (NO) inhalation was recognized as an effect treatment of Neonatal Persistent Pulmonary Hypertension (PPHN), while the safety of NO long term application was under investigation. Several research suggested too much NO2 was generated in the lung after long term (> 72h) use of NO inhalation, which cause bad effects on PS production.

Sildenafil was proved to be effective to PPHN as NO. This medication has a similar clinical effect but need monitoring of blood pressure. The possible hypotension effect restrict the dosage of sildenafil, which limit the usage of sildenafil in severe PPHN. But we recommend sildenafil to The purpose of the study was to establish if NO continued with sildenafil has the same effect as single NO inhalation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
— 至 28 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Diagnosed as PPHN in the NICU,primary disease:neonate respiratory distress syndrome,meconium aspiration syndrome of newborn,severe neonatal infectious pneumonia.
  • Pulmonary artery pressure > 50mmHg
  • mechanical ventilation over 48h
  • primary OI(PO2/FiO2)<300
  • difference of SpO2 between up and low limbs > 10%
  • high FiO2 oxygen inhalation test: positive

排除标准

  • congenital heart disease
  • diaphragmatic hernia

研究组 & 干预措施

NOS

Experimental

NO inhalation was performed in the first stage(<48h) of PPHN, NO inhalation was replaced by sildenafil in the second stage(>48h).

干预措施: NO inhalation continued with sildenafil (Drug)

NO

Placebo Comparator

NO inhalation was performed during the whole treatment procedure of PPHN. There is no other methods given to treat PPHN during the therapy course.

干预措施: NO inhalation (Drug)

结局指标

主要结局

persistent normal pulmonary artery pressure

时间窗: 96 hours

The pulmonary artery pressure returned back to a normal level(\<30mmHg) and last over 48 hours.

次要结局

  • Recover without complication(1 month after therapy)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验